Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Symbiosis Completes MHRA Audit of New Sterile Fill/Finish Facility | Contract Pharma
Breaking News

Symbiosis Completes MHRA Audit of New Sterile Fill/Finish Facility

Strengthens its position as a partner to biotechnology and pharmaceutical companies worldwide.

Symbiosis Pharmaceutical Services, a worldwide sterile fill/finish contract manufacturing organization (CMO), has successfully passed its recent audit conducted by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This follows an inspection of its newly constructed Bruce Building, a 20,000 sq ft aseptic facility that contains an automated fill/finish line for the sterile production of injectable drug products, including both small molecules and biologics.

This successful audit marks another step in Symbiosis’ £26 million strategic investment to scale its commercial manufacturing capabilities.

Formally opened by Scotland’s Deputy First Minister Kate Forbes in late 2024, the new expanded GMP facility enhances Symbiosis’ ability to deliver:

  • Aseptic fill/finish of liquid parenteral drug products
  • Handling of cytotoxic and high-potency compounds
  • Scalable batch sizes from preclinical to commercial

This regulatory endorsement reinforces Symbiosis’ commitment to global quality standards and strengthens its position as a trusted partner to biotechnology and pharmaceutical companies worldwide.

“This extension of our current MHRA licenses reflects the strength of our team and the robustness of our quality systems. For our clients, this solidifies confidence in our ability to accelerate the delivery of their sterile drug products to patients worldwide within a tightly regulated landscape,” said Colin MacKay, CEO of Symbiosis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters